Related Experiment Video
Updated: Jul 1, 2025

Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence
Published on: February 10, 2023
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells
Tajinder Ubhi1,2, Olga Zaslaver2, Andrew T Quaile2
1Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada.
Abstract:
Gemcitabine is a potent inhibitor of DNA replication and is a mainstay therapeutic for diverse cancers, particularly pancreatic ductal adenocarcinoma (PDAC). However, most tumors remain refractory to gemcitabine therapies. Here, to define the cancer cell response to gemcitabine, we performed genome-scale CRISPR-Cas9 chemical-genetic screens in PDAC cells and found selective loss of cell fitness upon disruption of the cytidine deaminases APOBEC3C and APOBEC3D. Following gemcitabine treatment, APOBEC3C and APOBEC3D promote DNA replication stress resistance and cell survival by deaminating cytidines in the nuclear genome to ensure DNA replication fork restart and repair in PDAC cells. We provide evidence that the chemical-genetic interaction between APOBEC3C or APOBEC3D and gemcitabine is absent in nontransformed cells but is recapitulated across different PDAC cell lines, in PDAC organoids and in PDAC xenografts. Thus, we uncover roles for APOBEC3C and APOBEC3D in DNA replication stress resistance and offer plausible targets for improving gemcitabine-based therapies for PDAC.
Insights
Gemcitabine resistance in pancreatic cancer is reduced by targeting APOBEC3C and APOBEC3D. These cytidine deaminases help cancer cells survive gemcitabine treatment by aiding DNA repair.
Area of Science:
- Cancer Biology
- Genetics
- Molecular Oncology
Background:
- Gemcitabine is a key chemotherapy for pancreatic ductal adenocarcinoma (PDAC).
- Tumor resistance limits gemcitabine's effectiveness in PDAC.
- Understanding cancer cell responses to gemcitabine is crucial for improving treatment.
Purpose of the Study:
- To identify genetic factors influencing cancer cell response to gemcitabine in PDAC.
- To investigate the role of cytidine deaminases APOBEC3C and APOBEC3D in gemcitabine resistance.
Main Methods:
- Genome-scale CRISPR-Cas9 chemical-genetic screens were conducted in PDAC cells.
- Analysis of cell fitness and DNA replication stress resistance following gemcitabine treatment.
- Validation in PDAC cell lines, organoids, and xenografts.
Main Results:
- Disruption of APOBEC3C and APOBEC3D led to a selective loss of cell fitness in PDAC cells treated with gemcitabine.
- APOBEC3C and APOBEC3D enhance DNA replication stress resistance and survival by deaminating nuclear cytidines, promoting replication fork restart and repair.
- The interaction between APOBEC3C/APOBEC3D and gemcitabine was specific to PDAC cells, not observed in non-transformed cells.
Conclusions:
- APOBEC3C and APOBEC3D play significant roles in conferring DNA replication stress resistance in PDAC cells.
- These cytidine deaminases are key mediators of gemcitabine resistance in pancreatic cancer.
- Targeting APOBEC3C and APOBEC3D presents a potential strategy to enhance gemcitabine-based therapies for PDAC.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
The DNA Replication Fork
Abnormal Proliferation
Negative Regulator Molecules
Restarting Stalled Replication Forks
S-Cdk Initiates DNA Replication
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...

